Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53.

Cell death and differentiation - 1 Sept 2010

Cheok C F, Kua N, Kaldis P, Lane D P

Abstract excerpt

Chemotherapeutics (e.g., aurora kinase inhibitors) designed to target proliferative cells are often nonspecific for tumor cells as normal cycling cells are also susceptible. Indeed, one of the major dose-limiting toxicities of aurora kinase inhibitors is a dangerous depletion of neutrophils in pa...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aurora Kinases
Share to Caffeine
Share to Cyclin B1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclin-Dependent Kinase Inhibitor p21

Share to G2 Phase

Share to Proto-Oncogene Proteins c-mdm2

Share to Tetraploidy

Share to Tumor Protein p73

Source

Identifiers

PMID: 20203688
DOI: 10.1038/cdd.2010.18

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20203688-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53.PMID 20203688Read ↗

Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapySemantic proximity Read ↗

Nongenotoxic p53 activation protects cells against S-phase-specific chemotherapy.Semantic proximity Read ↗

Revisiting p53 for cancer-specific chemo- and radiotherapy: ten years after.Semantic proximity Read ↗

Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapySemantic proximity Read ↗

Preferential killing of p53-deficient cancer cells by reversineSemantic proximity Read ↗

Induction of polyploidy and apoptosis after exposure to high concentrations of the spindle poison nocodazoleSemantic proximity Read ↗

Therapeutic Exploitation of Checkpoint Defects in Cancer Cells Lacking p53 FunctionSemantic proximity Read ↗

Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3.Semantic proximity Read ↗

The induction of polyploidy or apoptosis by the Aurora A kinase inhibitor MK8745 is p53-dependentSemantic proximity Read ↗

Cell-based screen for altered nuclear phenotypes reveals senescence progression in polyploid cells after Aurora kinase B inhibition.Semantic proximity Read ↗

Recent Advances in the Therapeutic Perspectives of Nutlin-3Semantic proximity Read ↗

p21 Downregulation is an important component of PAX3/FKHR oncogenicity and its reactivation by HDAC inhibitors enhances combination treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.